| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |